These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12900142)

  • 21. Some optimal control problems in cancer chemotherapy with a toxicity limit.
    Murray JM
    Math Biosci; 1990 Jun; 100(1):49-67. PubMed ID: 2134468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy.
    Boldrini JL; Costa MI
    IMA J Math Appl Med Biol; 2000 Mar; 17(1):33-51. PubMed ID: 10757031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-objective optimal chemotherapy control model for cancer treatment.
    Algoul S; Alam MS; Hossain MA; Majumder MA
    Med Biol Eng Comput; 2011 Jan; 49(1):51-65. PubMed ID: 20886373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function.
    Engelhart M; Lebiedz D; Sager S
    Math Biosci; 2011 Jan; 229(1):123-34. PubMed ID: 21129386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007.
    Wu Y; Aravind S; Ranganathan G; Martin A; Nalysnyk L
    Clin Ther; 2009; 31 Pt 2():2416-32. PubMed ID: 20110050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration sequence for multi-agent oncolytic regimens.
    Morales ASR; Joy JK; Zbona DM
    J Oncol Pharm Pract; 2020 Jun; 26(4):933-942. PubMed ID: 31964220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Model for tumour growth with treatment by continuous and pulsed chemotherapy.
    Borges FS; Iarosz KC; Ren HP; Batista AM; Baptista MS; Viana RL; Lopes SR; Grebogi C
    Biosystems; 2014 Feb; 116():43-8. PubMed ID: 24333154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs.
    Yoon N; Vander Velde R; Marusyk A; Scott JG
    Bull Math Biol; 2018 Jul; 80(7):1776-1809. PubMed ID: 29736596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A bilinear control model for tumor growth and chemotherapy.
    Vaidya VG; Alexandro FJ; Vaidya PG
    Int J Biomed Comput; 1985 Sep; 17(2):145-54. PubMed ID: 4055120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
    Jordan S; Steer C; DeFazio A; Quinn M; Obermair A; Friedlander M; Francis J; O'Brien S; Goss G; Wyld D; Australian Ovarian Cancer Study Group ; Webb P;
    Gynecol Oncol; 2013 May; 129(2):310-7. PubMed ID: 23403164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Principles for adjuvant and neoadjuvant chemotherapy].
    Fukuoka M; Tsuchiya R
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():333-7. PubMed ID: 7986112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in chemotherapy. Administration and nursing implications.
    Cawley MM
    Nurs Clin North Am; 1990 Jun; 25(2):377-91. PubMed ID: 2186387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.
    Levin L; Hryniuk WM
    J Clin Oncol; 1987 May; 5(5):756-67. PubMed ID: 3572465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia.
    Scholz M; Engel C; Loeffler M;
    Br J Haematol; 2006 Mar; 132(6):723-35. PubMed ID: 16487172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer chemotherapy: optimal control using the Verhulst-Pearl equation.
    Swan GW
    Bull Math Biol; 1986; 48(3-4):381-404. PubMed ID: 3828564
    [No Abstract]   [Full Text] [Related]  

  • 37. General applications of optimal control theory in cancer chemotherapy.
    Swan GW
    IMA J Math Appl Med Biol; 1988; 5(4):303-16. PubMed ID: 3241099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world utilization of darbepoetin alfa in cancer chemotherapy patients.
    Pan XL; Nordstrom BL; MacLachlan S; Lin J; Xu H; Sharma A; Chandler D; Li XS
    J Oncol Pharm Pract; 2019 Jan; 25(1):16-24. PubMed ID: 28814194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Dose intensity in cancer chemotherapy (including high dose chemotherapy)].
    Ariyoshi Y; Ogawa M
    Gan To Kagaku Ryoho; 1994 Dec; 21(16):2699-707. PubMed ID: 7993104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The significance of chronopharmacology for oncology].
    Hallek M; Lévi F; Haen E; Emmerich B
    Onkologie; 1989 Oct; 12(5):230-8. PubMed ID: 2685689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.